$2.42 Billion is the total value of Rock Springs Capital Management LP's 131 reported holdings in Q1 2020. The portfolio turnover from Q4 2019 to Q1 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISRG | INTUITIVE SURGICAL INC | $75,520,000 | -16.2% | 152,500 | 0.0% | 3.12% | +9.7% | |
| EHC | ENCOMPASS HEALTH CORP | $52,184,000 | -7.6% | 815,000 | 0.0% | 2.16% | +21.0% | |
| TFX | TELEFLEX INCORPORATED | $38,072,000 | -22.2% | 130,000 | 0.0% | 1.57% | +1.8% | |
| GLPG | GALAPAGOS NVspon adr | $34,286,000 | -5.3% | 175,000 | 0.0% | 1.42% | +24.0% | |
| SRPT | SAREPTA THERAPEUTICS INC | $33,797,000 | -24.2% | 345,500 | 0.0% | 1.40% | -0.9% | |
| ARGX | ARGENX SEsponsored adr | $32,603,000 | -17.9% | 247,500 | 0.0% | 1.35% | +7.4% | |
| CHRS | COHERUS BIOSCIENCES INC | $31,629,000 | -9.9% | 1,950,000 | 0.0% | 1.31% | +17.9% | |
| SGEN | SEATTLE GENETICS INC | $27,922,000 | +1.0% | 242,000 | 0.0% | 1.16% | +32.2% | |
| ARDX | ARDELYX INC | $27,572,000 | -24.3% | 4,850,000 | 0.0% | 1.14% | -0.9% | |
| BGNE | BEIGENE LTDsponsored adr | $26,444,000 | -25.7% | 214,800 | 0.0% | 1.09% | -2.8% | |
| AMGN | AMGEN INC | $25,544,000 | -15.9% | 126,000 | 0.0% | 1.06% | +10.0% | |
| ASND | ASCENDIS PHARMA A Ssponsored adr | $24,042,000 | -19.1% | 213,500 | 0.0% | 0.99% | +6.0% | |
| ASMB | ASSEMBLY BIOSCIENCES INC | $22,245,000 | -27.5% | 1,500,000 | 0.0% | 0.92% | -5.2% | |
| QURE | UNIQURE NV | $18,980,000 | -33.8% | 400,000 | 0.0% | 0.78% | -13.4% | |
| AMRN | AMARIN CORP PLCspons adr new | $18,600,000 | -81.3% | 4,650,000 | 0.0% | 0.77% | -75.6% | |
| INCY | INCYTE CORP | $18,308,000 | -16.1% | 250,000 | 0.0% | 0.76% | +9.7% | |
| ADPT | ADAPTIVE BIOTECHNOLOGIES COR | $15,140,000 | -7.2% | 545,000 | 0.0% | 0.63% | +21.6% | |
| GH | GUARDANT HEALTH INC | $13,224,000 | -10.9% | 190,000 | 0.0% | 0.55% | +16.6% | |
| KRTX | KARUNA THERAPEUTICS INC | $12,960,000 | -4.4% | 180,000 | 0.0% | 0.54% | +25.2% | |
| PHR | PHREESIA INC | $11,882,000 | -21.1% | 565,000 | 0.0% | 0.49% | +3.2% | |
| ODT | ODONATE THERAPEUTICS INC | $11,872,000 | -14.9% | 430,000 | 0.0% | 0.49% | +11.3% | |
| MNTA | MOMENTA PHARMACEUTICALS INC | $10,880,000 | +37.9% | 400,000 | 0.0% | 0.45% | +80.7% | |
| FGEN | FIBROGEN INC | $10,634,000 | -19.0% | 306,000 | 0.0% | 0.44% | +6.0% | |
| ALLK | ALLAKOS INC | $10,455,000 | -53.3% | 235,000 | 0.0% | 0.43% | -39.0% | |
| FOLD | AMICUS THERAPEUTICS INC | $9,240,000 | -5.1% | 1,000,000 | 0.0% | 0.38% | +24.0% | |
| RTRX | RETROPHIN INC | $8,389,000 | +2.7% | 575,000 | 0.0% | 0.35% | +34.5% | |
| CGEN | COMPUGEN LTDord | $7,986,000 | +21.8% | 1,100,000 | 0.0% | 0.33% | +59.4% | |
| CNST | CONSTELLATION PHARMCETICLS I | $7,339,000 | -33.3% | 233,500 | 0.0% | 0.30% | -12.9% | |
| MRSN | MERSANA THERAPEUTICS INC | $7,188,000 | +1.7% | 1,233,000 | 0.0% | 0.30% | +33.2% | |
| BHVN | BIOHAVEN PHARMACTL HLDG CO L | $6,806,000 | -37.5% | 200,000 | 0.0% | 0.28% | -18.3% | |
| FIXX | HOMOLOGY MEDICINES INC | $6,605,000 | -24.9% | 425,000 | 0.0% | 0.27% | -1.8% | |
| DVAX | DYNAVAX TECHNOLOGIES CORP | $5,560,000 | -38.3% | 1,575,000 | 0.0% | 0.23% | -19.3% | |
| INSMED INCnote 1.750% 1/1 | $5,040,000 | -13.0% | 6,000,000 | 0.0% | 0.21% | +13.7% | ||
| AKRO | AKERO THERAPEUTICS INC | $4,770,000 | -4.5% | 225,000 | 0.0% | 0.20% | +24.7% | |
| GRTX | GALERA THERAPEUTICS INC | $4,750,000 | -27.8% | 500,000 | 0.0% | 0.20% | -5.8% | |
| NGM | NGM BIOPHARMACEUTICALS INC | $4,329,000 | -33.3% | 351,100 | 0.0% | 0.18% | -12.7% | |
| MYOV | MYOVANT SCIENCES LTD | $3,775,000 | -51.4% | 500,000 | 0.0% | 0.16% | -36.3% | |
| AGLE | AEGLEA BIOTHERAPEUTICS INC | $3,728,000 | -39.0% | 800,000 | 0.0% | 0.15% | -20.2% | |
| PHAS | PHASEBIO PHARMACEUTICALS INC | $3,724,000 | -45.8% | 1,125,000 | 0.0% | 0.15% | -29.0% | |
| GMDA | GAMIDA CELL LTD | $3,020,000 | -29.8% | 1,000,000 | 0.0% | 0.12% | -8.1% | |
| CO | GLOBAL CORD BLOOD CORPORATIO | $2,942,000 | -36.4% | 925,000 | 0.0% | 0.12% | -16.4% | |
| ACRS | ACLARIS THERAPEUTICS INC | $1,664,000 | -45.0% | 1,600,000 | 0.0% | 0.07% | -28.1% | |
| THERAVANCE BIOPHARMA INCnote 3.250%11/0 | $1,448,000 | -7.0% | 1,500,000 | 0.0% | 0.06% | +22.4% | ||
| MGNX | MACROGENICS INC | $1,339,000 | -46.5% | 230,000 | 0.0% | 0.06% | -30.4% | |
| NEUROCRINE BIOSCIENCES INCnote 2.250% 5/1 | $1,287,000 | -16.2% | 1,000,000 | 0.0% | 0.05% | +8.2% | ||
| RADIUS HEALTH INCnote 3.000% 9/0 | $1,067,000 | -16.2% | 1,500,000 | 0.0% | 0.04% | +10.0% | ||
| PACIRA BIOSCIENCESnote 2.375% 4/0 | $966,000 | -7.3% | 1,000,000 | 0.0% | 0.04% | +21.2% | ||
| FPRX | FIVE PRIME THERAPEUTICS INC | $908,000 | -50.5% | 400,000 | 0.0% | 0.04% | -34.5% | |
| BMYRT | BRISTOL-MYERS SQUIBB COright 99/99/9999 | $704,000 | +26.4% | 185,150 | 0.0% | 0.03% | +61.1% | |
| CVET | COVETRUS INC | $168,000 | -38.5% | 20,683 | 0.0% | 0.01% | -22.2% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTUITIVE SURGICAL INC | 40 | Q3 2023 | 3.4% |
| NEUROCRINE BIOSCIENCES INC | 39 | Q3 2023 | 4.8% |
| PACIRA PHARMACEUTICALS INC | 39 | Q3 2023 | 2.6% |
| ULTRAGENYX PHARMACEUTICAL IN | 39 | Q3 2023 | 1.9% |
| ACADIA HEALTHCARE COMPANY IN | 38 | Q3 2023 | 4.4% |
| ASCENDIS PHARMA A/S | 35 | Q3 2023 | 1.3% |
| INVITAE CORP | 35 | Q3 2023 | 1.8% |
| BIOMARIN PHARMACEUTICAL INC | 35 | Q3 2023 | 1.3% |
| MACROGENICS INC | 35 | Q3 2023 | 0.5% |
| COLLEGIUM PHARMACEUTICAL INC | 34 | Q3 2023 | 2.1% |
View Rock Springs Capital Management LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Aeglea BioTherapeutics, Inc. | February 14, 2023 | 3,413,906 | 5.6% |
| Compass Therapeutics, Inc. | February 14, 2023 | 5,333,188 | 4.2% |
| Mirum Pharmaceuticals, Inc. | February 14, 2023 | 1,795,733 | 4.9% |
| PhaseBio Pharmaceuticals IncSold out | February 14, 2023 | 0 | 0.0% |
| Sierra Oncology, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| ARDELYX, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| CHIASMA, INCSold out | February 15, 2022 | 0 | 0.0% |
| FIVE PRIME THERAPEUTICS, INC.Sold out | February 15, 2022 | 0 | 0.0% |
| F-star Therapeutics, Inc. | February 15, 2022 | 751,889 | 3.6% |
| Protara Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
View Rock Springs Capital Management LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| SC 13G | 2024-05-01 |
| SC 13G/A | 2024-04-05 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View Rock Springs Capital Management LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.